Skip to main content
      IgG4 is a rare autoimmune disease with excessive IgG4 immunoglobulins that can affect multiple organs yielding plasma cell deposition (inflammation) and fibrosis.There has been great progress in treatment. Traditionally, glucocorticoids were used and if ineffective, then an oral immunesuppressive (ex: Azathioprine, MMF) and, if needed, rituximab. Many patients can improve sufficiently on this regimen.
      For the last several years, conversations about JAK inhibitors have often started and ended with safety. The shadow cast by ORAL Surveillance has made clinicians more cautious and regulators more restrictive. Yet in practice, many of us continue to reach for upadacitinib when we face challenges in treatment, from rheumatoid arthritis to axial spondyloarthritis. 
      RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All

      Dr. John Cush RheumNow

      1 week ago
      RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.
      CAR-T: The Future
      Secrets and Pearls in Rheumatology https://t.co/SwnlB8UbHO

      @Janetbirdope pearls in rheumatology.

      Sero negative infl

      Nouf Al hemmadi NoufAhmedAlham2

      1 week ago
      Secrets and Pearls in Rheumatology https://t.co/SwnlB8UbHO @Janetbirdope pearls in rheumatology. Sero negative inflammatory arthritis ? Or is it? Look at the toes for early signs of PsA. In my clinic ITS inflammatory arthritis to determine etiology . @RheumNow #ACR25
      Secukinumab vs Ustekinumab in PsA https://t.co/EylYHtRWsj

      @synovialjoints Elaborate more on head to head trial in

      Nouf Al hemmadi NoufAhmedAlham2

      1 week ago
      Secukinumab vs Ustekinumab in PsA https://t.co/EylYHtRWsj @synovialjoints Elaborate more on head to head trial in PsA , in a population who failed TNF biologic. @RheumNow #ACR25
      What's the latest in PsA? https://t.co/I8ZgRQpVy6

      Great review for whats new in PsA by @drpnash

      Looking forward for

      Nouf Al hemmadi NoufAhmedAlham2

      1 week ago
      What's the latest in PsA? https://t.co/I8ZgRQpVy6 Great review for whats new in PsA by @drpnash Looking forward for Large IL23-Axial study results. @RheumNow #ACR25
      Day 3 Recap- ACR Convergence 2025 Highlights https://t.co/4ZiTWVVwhl

      The analogy used by @RheumNow to explain differe

      Nouf Al hemmadi NoufAhmedAlham2

      1 week ago
      Day 3 Recap- ACR Convergence 2025 Highlights https://t.co/4ZiTWVVwhl The analogy used by @RheumNow to explain difference between completion versus intention to treat analysis hahahaha. You look good either ways! @bella_mehta @RHEUMarampa @EBRheum
      #ACR25 Abstr#LB15 Tell #RA patients on methotrexate that eating high fibre diet is good for them! An RCT showed improved

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 week ago
      #ACR25 Abstr#LB15 Tell #RA patients on methotrexate that eating high fibre diet is good for them! An RCT showed improved EULAR response vs PBO. Likely due to restoration of Th17/Treg balance @RheumNow https://t.co/NbwQFqJNho
      #ACR25 Abstr#LB14 Promising therapyBMS-986353, a CD19 CAR-T in Severe Refractory Idiopathic Inflammatory Myopathies. 11

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 week ago

      #ACR25 Abstr#LB14 Promising therapy BMS-986353, a CD19 CAR-T in Severe Refractory Idiopathic Inflammatory Myopathies. 11/12 had evaluable data; muscle, skin and ILD improved. 1 x G2 CRS, 1 G3 ICANS. Longer FU needed and larger sample @RheumNow https://t.co/zAG23tAsbL

      #ACR25 Abstr#2411 How good is performance of 2019 ACR-EULAR #SLE criteria at the point of diagnosis in At-Risk ANA+ peop

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 week ago
      #ACR25 Abstr#2411 How good is performance of 2019 ACR-EULAR #SLE criteria at the point of diagnosis in At-Risk ANA+ people? Our group compared this with Clinician dx -> high specificity(93.8%); low sensitivity(79.3%). Might be a cause why SMILE HCQ RCT failed in At-Risk @RheumNow https://t.co/6GNU2B2wvj
      Cohort study comparing 3yr safety outcomes of JAKi vs. TNFi in AS pts

      JAKi use: ⬆️incidence of HZ infxn but not sig

      sheila RHEUMarampa

      1 week 1 day ago
      Cohort study comparing 3yr safety outcomes of JAKi vs. TNFi in AS pts JAKi use: ⬆️incidence of HZ infxn but not significant; ⬆️all-cause mortality (HR 4.94) and GI bleed (p=0.04) Individualize tx. consider potential complications #ACR25 @RheumNow Abs2633 https://t.co/pjKAazQFwW
      ×